Home/Filings/4/0000899243-23-003891
4//SEC Filing

Carey John F 4

Accession 0000899243-23-003891

CIK 0001756262other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 5:12 PM ET

Size

21.5 KB

Accession

0000899243-23-003891

Insider Transaction Report

Form 4
Period: 2023-02-01
Carey John F
VP of Operations
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-02-014713,543 total
    Exercise: $38.46Exp: 2031-02-24Common Stock (47 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-02-011,3634,887 total
    Exercise: $16.14Exp: 2030-02-27Common Stock (1,363 underlying)
  • Exercise/Conversion

    Common Stock

    2023-02-01$16.14/sh+1,363$21,99915,483 total
  • Exercise/Conversion

    Common Stock

    2023-02-01$38.46/sh+47$1,80815,530 total
  • Sale

    Common Stock

    2023-02-01$62.52/sh379$23,69514,569 total
  • Sale

    Common Stock

    2023-02-01$64.04/sh96$6,14814,473 total
  • Sale

    Common Stock

    2023-02-01$64.88/sh139$9,01814,334 total
  • Sale

    Common Stock

    2023-02-01$62.00/sh582$36,08414,948 total
  • Sale

    Common Stock

    2023-02-01$65.81/sh214$14,08314,120 total
Footnotes (8)
  • [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.23 to $62.22, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.23 to $63.02, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $63.43 to $64.41, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F5]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $64.45 to $65.42, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F6]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.45 to $65.96, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F7]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020.
  • [F8]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.

Issuer

TransMedics Group, Inc.

CIK 0001756262

Entity typeother

Related Parties

1
  • filerCIK 0001774272

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 5:12 PM ET
Size
21.5 KB